Subject: EAPH - Sub Penny Pharma-pick with small
Post# of 451
Posted On: 06/04/2013 11:06:36 PM
Subject: EAPH - Sub Penny Pharma-pick with small float could go parabolic tomorrow
The Next Upcoming Mega Market Mover- EAPH is a New Penny "Blockbuster-Pharmaceutical'' Play (trading at only .0081 cents)
EAPH could go Parabolic tomorrow being that its an undiscovered Gem play with a tiny float of 63MM shares and a tiny outstanding share count of only 128MM as of May 2013 http://www.otcmarkets.com/stock/EAPH/company-info .
EAPH market cap is dirt cheap right now and still UNDER $1MM so there is Mega Upside potential here. EAPH looks to be the hidden Wallstreet gem with Mega upside potential having a product that could be considered the Next V-I-A-G-R-A for Women.
EAPH flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal, FSAD (Female-Sexual-Arousal-Disorder). The world market for products which treat this disorder is in excess of US$2 BB.
EAPH proprietary gel formulation is an innovative and unique transdermal delivery system. EAPH flagship product, VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.
EAPH - Breaking News just Released Tonight after market hours
Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer
TORONTO--(BUSINESS WIRE)--Easton Pharmaceuticals (EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, announced today that Mr. Neil Mellor will join the company as Senior Consultant, Chief Operations Officer. Mr. Mellor has over 25 years of experience in the pharmaceutical industry, both in Canada and Europe. The majority of Mr. Mellor’s background is in sales, marketing and business development for companies such as Merck, Pharmacia (now Pfizer), and Solvay Pharma (now Abbott Laboratories).
Over the past 10 years, Mr. Mellor has been Associate Director of Business Development at Solvay Pharma. In addition, Mr. Mellor served as President of the Canadian Healthcare Licensing Association (CHLA) from 2007 to 2008 and remains an active member of the Board of the CHLA. Mr. Mellor is currently the President of Global Health Link, a healthcare consulting company serving Canadian and US clients. We are especially pleased to have such an accomplished professional as Mr. Mellor on board to help with our future plans for our products, beginning with our lead product VIORRA TM,” commented Mr. John Adams, of Easton Pharmaceuticals’. "Mr. Mellor’s vast experience in marketing and licensing will help us navigate the sometimes uncertain waters of the different markets Easton Pharmaceuticals is considering, and will help us focus on the design and execution of key business activities which will enrich our pending commercialization efforts.”
About Easton Pharmaceuticals Inc (EAPH):
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding numbers of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins. The world market for these conditions is in excess of US$10 BB.
The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal , FSAD (Female-Sexual-Arousal-Disorder). The world market for products which treat this disorder is in excess of US$2 BB. VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.
For more information, visit http://www.eastonpharma.com/ or http://www.ashleybiomedical.com/
Contact:
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email and Media Relations: info@lamindustries.com
Email and Media Relations: info@ashleybiomedical.com
Contact:
Easton Pharmaceuticals Inc.
Dragoslav Milanovic, CEO
+1-416-619-0291
+1-347-284-0192
or
Media Relations:
info@lamindustries.com
or
info@ashleybiomedical.com
The Next Upcoming Mega Market Mover- EAPH is a New Penny "Blockbuster-Pharmaceutical'' Play (trading at only .0081 cents)
EAPH could go Parabolic tomorrow being that its an undiscovered Gem play with a tiny float of 63MM shares and a tiny outstanding share count of only 128MM as of May 2013 http://www.otcmarkets.com/stock/EAPH/company-info .
EAPH market cap is dirt cheap right now and still UNDER $1MM so there is Mega Upside potential here. EAPH looks to be the hidden Wallstreet gem with Mega upside potential having a product that could be considered the Next V-I-A-G-R-A for Women.
EAPH flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal, FSAD (Female-Sexual-Arousal-Disorder). The world market for products which treat this disorder is in excess of US$2 BB.
EAPH proprietary gel formulation is an innovative and unique transdermal delivery system. EAPH flagship product, VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.
EAPH - Breaking News just Released Tonight after market hours
Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer
TORONTO--(BUSINESS WIRE)--Easton Pharmaceuticals (EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, announced today that Mr. Neil Mellor will join the company as Senior Consultant, Chief Operations Officer. Mr. Mellor has over 25 years of experience in the pharmaceutical industry, both in Canada and Europe. The majority of Mr. Mellor’s background is in sales, marketing and business development for companies such as Merck, Pharmacia (now Pfizer), and Solvay Pharma (now Abbott Laboratories).
Over the past 10 years, Mr. Mellor has been Associate Director of Business Development at Solvay Pharma. In addition, Mr. Mellor served as President of the Canadian Healthcare Licensing Association (CHLA) from 2007 to 2008 and remains an active member of the Board of the CHLA. Mr. Mellor is currently the President of Global Health Link, a healthcare consulting company serving Canadian and US clients. We are especially pleased to have such an accomplished professional as Mr. Mellor on board to help with our future plans for our products, beginning with our lead product VIORRA TM,” commented Mr. John Adams, of Easton Pharmaceuticals’. "Mr. Mellor’s vast experience in marketing and licensing will help us navigate the sometimes uncertain waters of the different markets Easton Pharmaceuticals is considering, and will help us focus on the design and execution of key business activities which will enrich our pending commercialization efforts.”
About Easton Pharmaceuticals Inc (EAPH):
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding numbers of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins. The world market for these conditions is in excess of US$10 BB.
The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal , FSAD (Female-Sexual-Arousal-Disorder). The world market for products which treat this disorder is in excess of US$2 BB. VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.
For more information, visit http://www.eastonpharma.com/ or http://www.ashleybiomedical.com/
Contact:
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email and Media Relations: info@lamindustries.com
Email and Media Relations: info@ashleybiomedical.com
Contact:
Easton Pharmaceuticals Inc.
Dragoslav Milanovic, CEO
+1-416-619-0291
+1-347-284-0192
or
Media Relations:
info@lamindustries.com
or
info@ashleybiomedical.com
(0)
(0)Easton Pharmaceuticals Inc (EAPH) Stock Research Links
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
Scroll down for more posts ▼